ACTU

Actuate Therapeutics, Inc. Common stock

NASDAQ: ACTU · HEALTHCARE · BIOTECHNOLOGY

$2.98

-3.09% today

Updated 2026-06-05

Market cap

$47.61M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.98

Dividend yield

—

52W range

$2 – $10

Volume

0.2M

Market cap

$47.61M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.98

Dividend yield

—

52W range

$2 – $10

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.3

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$9.98

+235.46%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.11x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-5.02M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-20.16M	$-24.74M	$-27.29M	$-22.23M	$-5.63M
EPS	—	—	—	—	$-0.98
Free cash flow	$-17.79M	$-21.63M	$-21.84M	$-19.21M	$-5.02M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ACTU	$47.61M	20	4.3	3.0	5.0	6.3	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Actuate Therapeutics, Inc. Common stock trades at $2.98. Our Smart Value Score of 20/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Actuate Therapeutics, Inc. Common stock's stock price?

Actuate Therapeutics, Inc. Common stock (ACTU) trades at $2.98.

Is Actuate Therapeutics, Inc. Common stock overvalued?

Actuate Therapeutics, Inc. Common stock carries a Smart Value Score of 20/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Actuate Therapeutics, Inc. Common stock (ACTU)?

The 12-month analyst consensus target is $9.98, about 235.5% above the current $2.98. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-569.09%

Beta—

50D MA$2.49

200D MA$5.24

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ACTU vs LLY →ACTU vs JNJ →ACTU vs ABBV →Stock screener →